Literature DB >> 27924395

The effect of postoperative complications on survival of patients after minimally invasive esophagectomy for esophageal cancer.

Kun-Kun Li1, Yin-Jian Wang1, Xue-Hai Liu1, Qun-You Tan1, Yao-Guang Jiang1, Wei Guo2.   

Abstract

BACKGROUND: Minimally invasive esophagectomy (MIE) has been shown to be a feasible technique for the treatment of esophageal cancer; however, its postoperative morbidity remains high. This retrospective study aimed to evaluate the effect of postoperative complications on long-term outcomes in patients who have undergone MIE for esophageal squamous cell carcinoma (ESCC).
METHODS: This retrospective study enrolled patients who had undergone MIE for ESCC between September 2009 and November 2014; all procedures were performed by a single surgical team. Relevant patient characteristics and postoperative variables were collected and evaluated. The disease-free survival (DFS) and disease-specific survival (DSS) were determined by the Kaplan-Meier method, and compared by log-rank tests. Possible predictors of survival were subjected to univariate analysis and multivariate Cox proportional hazard regression analysis.
RESULTS: In all, data on 214 patients with ESCC were analyzed, including 170 men and 44 women. All study subjects had undergone thoracoscopic or thoracoscopic-laparoscopic esophagectomy and cervical esophagogastric anastomosis. One hundred and thirty patients (60.7%) had postoperative complications (Grades 1-4). The overall DFS and DSS rates were 80.0 and 88.9% at 1 year, 48.6 and 54.2% at 3 years, and 43.2 and 43.5% at 5 years, respectively. Univariate analysis and multivariate Cox proportional hazard regression analysis showed that T stage, N stage, and tumor grade were independent prognostic factors for long-term survival; however, postoperative complications had no significant effect on the DFS or DSS of this patient cohort (log-rank test, p = 0.354 and 0.160, respectively).
CONCLUSIONS: Postoperative complications have no significant effect on long-term survival in patients who have undergone MIE for ESCC.

Entities:  

Keywords:  Clavien classification; Complication; Esophageal cancer; Minimally invasive esophagectomy; Survival

Mesh:

Year:  2016        PMID: 27924395     DOI: 10.1007/s00464-016-5372-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  24 in total

1.  Minimally invasive esophagectomy provides significant survival advantage compared with open or hybrid esophagectomy for patients with cancers of the esophagus and gastroesophageal junction.

Authors:  Francesco Palazzo; Ernest L Rosato; Asadulla Chaudhary; Nathaniel R Evans; Jocelyn A Sendecki; Scott Keith; Karen A Chojnacki; Charles J Yeo; Adam C Berger
Journal:  J Am Coll Surg       Date:  2014-12-27       Impact factor: 6.113

2.  What is a surgical complication?

Authors:  Daniel Dindo; Pierre-Alain Clavien
Journal:  World J Surg       Date:  2008-06       Impact factor: 3.352

3.  A comparative study of survival after minimally invasive and open oesophagectomy.

Authors:  Oliver C Burdall; Alexander P Boddy; James Fullick; Jane Blazeby; Richard Krysztopik; Christopher Streets; Andrew Hollowood; Christopher P Barham; Dan Titcomb
Journal:  Surg Endosc       Date:  2014-08-15       Impact factor: 4.584

4.  Comparison of the outcomes between open and minimally invasive esophagectomy.

Authors:  Bernard M Smithers; David C Gotley; Ian Martin; Janine M Thomas
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

5.  Thoracolaparoscopy in the lateral position for esophageal cancer: the experience of a single institution with 112 consecutive patients.

Authors:  Shailesh P Puntambekar; Geetanjali A Agarwal; Saurabh N Joshi; Neeraj V Rayate; Ravindra M Sathe; Anjali M Patil
Journal:  Surg Endosc       Date:  2010-03-05       Impact factor: 4.584

6.  Prevention of postoperative chylothorax with thoracic duct ligation during video-assisted thoracoscopic esophagectomy for cancer.

Authors:  Wei Guo; Yun-Ping Zhao; Yao-Guang Jiang; Hui-Jun Niu; Xue-Hai Liu; Zheng Ma; Ru-Wen Wang
Journal:  Surg Endosc       Date:  2011-11-02       Impact factor: 4.584

7.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

8.  Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China.

Authors:  Gina D Tran; Xiu-Di Sun; Christian C Abnet; Jin-Hu Fan; Sanford M Dawsey; Zhi-Wei Dong; Steven D Mark; You-Lin Qiao; Philip R Taylor
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

9.  Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification.

Authors:  Toni Lerut; Johnny Moons; Willy Coosemans; Dirk Van Raemdonck; Paul De Leyn; Herbert Decaluwé; Georges Decker; Philippe Nafteux
Journal:  Ann Surg       Date:  2009-11       Impact factor: 12.969

10.  A comparison of video-assisted thoracoscopic oesophagectomy and radical lymph node dissection for squamous cell cancer of the oesophagus with open operation.

Authors:  H Osugi; M Takemura; M Higashino; N Takada; S Lee; H Kinoshita
Journal:  Br J Surg       Date:  2003-01       Impact factor: 6.939

View more
  8 in total

1.  Predictive factors of difficulty of thoracoscopic esophagectomy in the left decubitus position.

Authors:  Yushi Fujiwara; Shigeru Lee; Ken Gyobu; Daiki Inazu; Ryoko Naka; Masaki Nishiyama; Masaichi Ohira; Harushi Osugi
Journal:  Esophagus       Date:  2019-04-30       Impact factor: 4.230

2.  Minimally invasive esophagectomy for esophageal squamous cell carcinoma-Shanghai Chest Hospital experience.

Authors:  Bin Li; Yu Yang; Yifeng Sun; Rong Hua; Xiaobin Zhang; Xufeng Guo; Haiyong Gu; Bo Ye; Zhigang Li; Teng Mao
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 3.  Technique of robotic assisted minimally invasive esophagectomy (RAMIE).

Authors:  Olugbenga T Okusanya; Nicholas R Hess; James D Luketich; Inderpal S Sarkaria
Journal:  J Vis Surg       Date:  2017-08-31

4.  Favorable clinical outcomes of total robotic esophagectomy for esophageal cancer.

Authors:  Noriyuki Hirahara; Yoshitsugu Tajima
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 2.895

5.  Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.

Authors:  Yushi Fujiwara; Shigeru Lee; Satoru Kishida; Ryoya Hashiba; Ken Gyobu; Ryoko Naka; Masaki Nishiyama; Toshio Ihara; Masashi Takemura; Harushi Osugi
Journal:  Int J Clin Oncol       Date:  2018-05-11       Impact factor: 3.402

6.  The survival impact of postoperative complications after curative resection in patients with esophageal squamous cell carcinoma: propensity score-matching analysis.

Authors:  Manabu Yamamoto; Mototsugu Shimokawa; Daisuke Yoshida; Shohei Yamaguchi; Mitsuhiko Ohta; Akinori Egashira; Masahiko Ikebe; Masaru Morita; Yasushi Toh
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-17       Impact factor: 4.553

7.  Postoperative morbidity adversely impacts oncological prognosis after curative resection for hilar cholangiocarcinoma.

Authors:  Zhi-Peng Liu; Wei-Yue Chen; Yan-Qi Zhang; Yan Jiang; Jie Bai; Yu Pan; Shi-Yun Zhong; Yun-Ping Zhong; Zhi-Yu Chen; Hai-Su Dai
Journal:  World J Gastroenterol       Date:  2022-03-07       Impact factor: 5.742

8.  Overexpression of U three protein 14a (UTP14a) is associated with poor prognosis of esophageal squamous cell carcinoma.

Authors:  Kun-Kun Li; Cheng-Yi Mao; Jing-Ge Zhang; Qiang Ma; Ying-Jian Wang; Xue-Hai Liu; Tao Bao; Wei Guo
Journal:  Thorac Cancer       Date:  2019-09-08       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.